More on Regeneron's (REGN) Q1 : The company exhibits "sustained revenue and earnings growth"...

|About: Regeneron Pharmaceuticals, ... (REGN)|By:, SA News Editor

More on Regeneron's (REGN) Q1 : The company exhibits "sustained revenue and earnings growth" helped by strong EYLEA sales growth in the U.S. (FY13 U.S. sales estimates for the macular degeneration injection hiked to $1.25-1.325B) and a healthy roll out of the drug outside the country by partner Bayer Healthcare. Late stage pipeline makes progress. Shares +5% premarket. ( PR )